<DOC>
	<DOC>NCT01084330</DOC>
	<brief_summary>A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.</brief_summary>
	<brief_title>Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Radiologically confirmed advanced gastric cancer One previous line of chemotherapy Progressive disease One measurable lesion Blood tests within protocol ranges (WHO) Performance Status â‰¤ 1 Able to sign informed consent No symptomatic brain metastases No coumarin type anticoagulants No liver or kidney disease No impaired heart function No pregnant or lactating women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>metastatic gastric cancer</keyword>
	<keyword>advanced gastric cancer</keyword>
</DOC>